Dabrafenib: First Global Approval

Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options

(2013) Kathryn A Culos et al.   ANNALS OF PHARMACOTHERAPY

Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations

(2013) Giusy Gentilcore et al.   BMC CANCER

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Update on the Targeted Therapy of Melanoma

(2013) Douglas B. Johnson et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Which drug, and when, for patients with BRAF-mutant melanoma?

(2013) Sekwon Jang et al.   LANCET ONCOLOGY

BRAF inhibitor activity in V600R metastatic melanoma

(2012) Oliver Klein et al.   EUROPEAN JOURNAL OF CANCER

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

(2012) Georgina V Long et al.   LANCET ONCOLOGY

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE